Search details
1.
The current state of molecular testing in the treatment of patients with solid tumors, 2019.
CA Cancer J Clin
; 69(4): 305-343, 2019 07.
Article
in English
| MEDLINE | ID: mdl-31116423
2.
Investigating potential immune mechanisms of trilaciclib administered prior to chemotherapy in patients with metastatic triple-negative breast cancer.
Breast Cancer Res Treat
; 201(2): 307-316, 2023 Sep.
Article
in English
| MEDLINE | ID: mdl-37418031
3.
Checkpoint inhibitor therapy for metastatic triple-negative breast cancer.
Cancer Metastasis Rev
; 40(2): 537-547, 2021 06.
Article
in English
| MEDLINE | ID: mdl-34101053
4.
Molecular characterization of ESR1 variants in breast cancer.
Breast Cancer Res Treat
; 196(2): 279-289, 2022 Nov.
Article
in English
| MEDLINE | ID: mdl-36125660
5.
Does Residual Cancer Burden Predict Local Recurrence After Neoadjuvant Chemotherapy?
Ann Surg Oncol
; 29(12): 7716-7724, 2022 Nov.
Article
in English
| MEDLINE | ID: mdl-35810226
6.
Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2.
Future Oncol
; 18(33): 3701-3711, 2022 Oct.
Article
in English
| MEDLINE | ID: mdl-36135712
7.
Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.
Lancet Oncol
; 22(1): 85-97, 2021 01.
Article
in English
| MEDLINE | ID: mdl-33357420
8.
Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer.
Breast Cancer Res Treat
; 189(2): 377-386, 2021 Sep.
Article
in English
| MEDLINE | ID: mdl-34264439
9.
The evolving role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer.
Clin Adv Hematol Oncol
; 19(5): 305-315, 2021 May.
Article
in English
| MEDLINE | ID: mdl-33989278
10.
Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway.
Breast Cancer Res Treat
; 184(2): 265-275, 2020 Nov.
Article
in English
| MEDLINE | ID: mdl-32776290
11.
Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial.
Lancet Oncol
; 20(11): 1587-1601, 2019 11.
Article
in English
| MEDLINE | ID: mdl-31575503
12.
Development of poly(ADP-ribose) polymerase inhibitors in the treatment of BRCA-mutated breast cancer.
Clin Adv Hematol Oncol
; 16(7): 491-501, 2018 Jul.
Article
in English
| MEDLINE | ID: mdl-30067621
13.
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Oncol
; 18(10): 1360-1372, 2017 10.
Article
in English
| MEDLINE | ID: mdl-28800861
14.
A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer.
Breast Cancer Res Treat
; 163(3): 535-544, 2017 06.
Article
in English
| MEDLINE | ID: mdl-28324268
15.
A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer.
Breast Cancer Res Treat
; 165(3): 601-609, 2017 Oct.
Article
in English
| MEDLINE | ID: mdl-28681171
16.
ASO Visual Abstract: Does Residual Cancer Burden Predict Local Recurrence after Neoadjuvant Chemotherapy?
Ann Surg Oncol
; 29(12): 7725, 2022 Nov.
Article
in English
| MEDLINE | ID: mdl-36100831
17.
Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers.
Oncologist
; 21(11): 1315-1325, 2016 Nov.
Article
in English
| MEDLINE | ID: mdl-27566247
18.
Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor ß by the monoclonal antibody fresolimumab (GC1008).
Cancer Immunol Immunother
; 64(4): 437-46, 2015 Apr.
Article
in English
| MEDLINE | ID: mdl-25579378
19.
Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9.
Breast Cancer Res Treat
; 152(2): 399-405, 2015 Jul.
Article
in English
| MEDLINE | ID: mdl-26126970
20.
Tripartite Motif-containing 33 (TRIM33) protein functions in the poly(ADP-ribose) polymerase (PARP)-dependent DNA damage response through interaction with Amplified in Liver Cancer 1 (ALC1) protein.
J Biol Chem
; 288(45): 32357-32369, 2013 Nov 08.
Article
in English
| MEDLINE | ID: mdl-23926104